Fig. 1From: Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinomaCorrelation between amount of CTNNB1-mutated alleles with 95% confidence intervals during follow up and clinical course of disease in five HCC patients. a Patient underwent resection and concomittant radiofrequency ablation. Relapse diagnosed on CT scans after 1 year. b Patient received sorafenib. Stopped treatment after 8 weeks because of progressive disease and declining performance status. c Patient underwent radiofrequency ablation with complete response. d Patient received Trans Arterial Chemo Embolization with a mixed response. e Patient recieved sorafenib. Stopped treatment due to declining performance status. Deceased after 6 monthsBack to article page